ライフサイエンスコーパス: papillary

1 /oxyphilic carcinomas (4/4 patients) than in papillary (1/5) or follicular (0/6) tumors.

2 , 47 (36%) had incidental thyroid cancer (24 papillary, 11 malignant FNA, 5 oncocytic/Hurthle cell, 2

3 n of this disease: 1) Most UTUCs are luminal-papillary; 2) UTUC has a T-cell depleted immune contextu

4 study was conducted on 273 female cases (210 papillary, 45 follicular, and 18 not otherwise specified

5 Papillary adenocarcinoma was significantly more frequent

6 Papillary adenoma (PA) is a small benign lesion morpholo

7 apy options exist for patients with advanced papillary and anaplastic thyroid cancer.

8 The mean ER of clear cell, papillary and chromophobe RCC were 188+/-49.7, 35+/-8.9,

9 The mean WR of clear cell, papillary and chromophobe RCCs were 28.6+/-6.8, 47.6+/-5

10 cy, and histologic fidelity, these models of papillary and clear cell RCC should be significant contr

11 in anaplastic thyroid cancers compared with papillary and follicular subtypes (P < 0.0001).

12 storation of iodide uptake in RAI-refractory papillary and follicular thyroid cancer cell lines.

13 ly exclusive desmoplasia and inflammation in papillary and follicular thyroid cancers and the presenc

14 apoptosis and induction of migration in both papillary and follicular thyroid carcinoma cell lines.

15 Histology indicated papillary and interstitial fibrosis with ageing, which w

16 rs achieved their lowest values in mucinous, papillary and medullary carcinomas, whereas the highest

17 Papillary and micropapillary adenocarcinomas and nodal m

18 cers, develops via two tracks referred to as papillary and nonpapillary that correspond to clinically

19 corresponding to the transition between the papillary and reticular dermis.

20 olved nests of basaloid cells present in the papillary and reticular dermis.

21 CD8+ T cells were rather located in both the papillary and reticular layers of the LP.

22 noma), papillary (pRCC, also known as kidney papillary) and chromophobe (chRCC, also known as kidney

23 f cancer (one each of prostate, colon, renal papillary, and rectal cancer and three nonmelanoma skin

24 alignant masses (including 41 clear cell, 20 papillary, and seven chromophobe renal cell carcinomas [

25 t with luminal and basal subtypes, including papillary architecture and squamous differentiation.

26 t mesenchymal FGF10 controls the size of the papillary area, while overall patterning remains unchang

27 doscopic sphincterotomy (EST) and endoscopic papillary balloon dilation (EPBD) can be challenging, re

28 sphincterotomy (PS) combined with endoscopic papillary balloon dilation (EPBD) for CBD stone removal

29 ated by endoscopic sphincterotomy/endoscopic papillary balloon dilation (EST/EPBD) with negative ERC

30 Methods: Papillary (BcPAP) and anaplastic (CAL62 and FRO82-1) thy

31 th [DMF-T] index); 2) gingival inflammation (papillary bleeding index [PBI]); and 3) periodontal stat

32 imaging enabled clear visualization of fine papillary branches in serous BOT and allowed for charact

33 kemia, oligodendroglioma, astrocytoma, solid papillary breast carcinoma with reverse polarity, sinona

34 aluated in clear cell (786-O and Caki-1) and papillary (Caki-2 and ACHN) RCC cells.

35 re reported for all participants, those with papillary cancer only, and women only.

36 Most cancers were papillary carcinoma (68 [88.3%] of 77).

37 and malignant follicular carcinoma (FTC) and papillary carcinoma (PTC) thyroid tissues.

38 Higher CXCR6 expression in serous papillary carcinoma tissues suggests its association wit

39 Solid papillary carcinoma with reverse polarity (SPCRP) is a r

40 re as follows: clear cell carcinomas (n=23), papillary carcinomas (n=6), and chromophobe carcinomas (

41 alphavbeta3-positive vessels in the group of papillary carcinomas whereas it correlated with integrin

42 nes, severe cystic pathology, and ultimately papillary carcinomas with hepatic metastases.

43 nomas); and group C (medullary, mucinous and papillary carcinomas).

44 the cases were histologically classified as papillary carcinomas, with 2 of them exhibiting follicul

45 In Brassicaceae, the dry stigmatic papillary cells control pollen germination by releasing

46 ealed features of overt differentiation with papillary characteristics.

47 We enrolled patients with metastatic papillary, chromophobe, or unclassified non-clear cell r

48 Finally, we reveal that papillary craniopharyngioma (PCP), a benign human pituit

49 adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP), differ in genesis and

50 gical reconstructive approaches for treating papillary deficiency associated with soft and hard tissu

51 multiple superficial microdisruptions in the papillary dermis and epidermis.

52 nse dermal nests, and nucleated cells within papillary dermis, were more frequently found in this sub

53 the epidermis, although also evident in the papillary dermis.

54 tic of type II ECs, including focal areas of papillary differentiation, protruding cytoplasm into the

55 Intravascular papillary endothelial hyperplasia (IPEH), also known as

56 Radiologically, intravascular papillary endothelial hyperplasia could be misdiagnosed

57 ARID1A were seen in five of 14 patients with papillary features but not in other RCC variants.

58 Presence of papillary features were associated with benefit, includi

59 tion in patients with ncRCC characterized by papillary features.

60 pidermal Shh stimulates proliferation of the papillary fibroblast lineage, whereas TGF-beta2 controls

61 rate but with a reduction in Lrig1-positive papillary fibroblasts in wounds.

62 and developing skin, we identified neonatal papillary fibroblasts that form a transient regenerative

63 does not prevent Hh target gene induction in papillary fibroblasts.

64 Papillary fibroelastomas (PFE) are benign neoplasms with

65 ominant in endocardium and is accompanied by papillary fibrosis.

66 The majority of patients had papillary growth as a major component (n = 14).

67 ges, including midfacial recession (MFR) and papillary height (PH) loss.

68 d at the participating centres, 66 (59%) had papillary histology, 17 (15%) had Xp11.2 translocation h

69 Sloan Kettering Cancer Center risk group and papillary histology.

70 paces (confirmed by CLE), and basal cell and papillary hyperplasia developed without surface erosions

71 t esophageal inflammation and basal cell and papillary hyperplasia without loss of surface cells.

72 ed were changes in epithelial basal cell and papillary hyperplasia, surface erosions, intercellular s

73 the efficacy of limited EST plus endoscopic papillary large balloon dilation (EST-EPLBD) for large b

74 s) were found in both the epithelium and the papillary layer of the Lamina propria (LP), whereas CD68

75 ytic and invasive components associated with papillary lesions (pSCCs) and invasive SCCs without exop

76 developed sporadic, macroscopic, intraductal papillary lesions with histologic and molecular features

77 solution of OCT enables the detection of the papillary loops.

78 ial progenitor cells via field effects along papillary/luminal and nonpapillary/basal pathways.

79 an extent of cutting < 1/2 the length of the papillary mound.

80 RI revealed a pancreatic lesion: intraductal papillary mucinous neoplasia (14 patients, 35%) and panc

81 One patient had a synchronous intraductal papillary mucinous neoplasia and pancreatic ductal adeno

82 ductal adenocarcinoma and 2 for intraductal papillary mucinous neoplasia), while the remaining 35 ar

83 sitive lymph nodes, a context of intraductal papillary mucinous neoplasia, and vascular resections we

84 BACKGROUND & AIMS: Intraductal papillary mucinous neoplasias (IPMNs) are precancerous c

85 y of pancreatic branch-duct (BD) intraductal papillary mucinous neoplasm (IPMN) is infrequent and tha

86 epithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) precursor lesions.

87 Human intraductal papillary mucinous neoplasm (IPMN) specimens were analyz

88 AC) and its preneoplastic lesion intraductal papillary mucinous neoplasm (IPMN), to find new microRNA

89 asive carcinoma in patients with intraductal papillary mucinous neoplasm (IPMN).

90 e after pancreatic resection for intraductal papillary mucinous neoplasm (IPMN).

91 urgery, only one patient with an intraductal papillary mucinous neoplasm had high-grade dysplasia.

92 6 were more commonly detected in intraductal papillary mucinous neoplasm-associated PDACs.

93 t the development of branch duct intraductal papillary mucinous neoplasms (BD-IPMNs).

94 guidelines for the management of intraductal papillary mucinous neoplasms (IPMN) recommend surgical t

95 llowing resection for pancreatic intraductal papillary mucinous neoplasms (IPMN) using targeted next-

96 pseudocysts, 2 cysts/remnants, 4 intraductal papillary mucinous neoplasms (IPMN), 2 adenocarcinomas,

97 n about the origin of pancreatic intraductal papillary mucinous neoplasms (IPMN).

98 docrine tumors (PanNET, n = 42), intraductal papillary mucinous neoplasms (IPMN, n = 20), and ampulla

99 Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic

100 cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of t

101 Among PCNs, Intraductal Papillary Mucinous Neoplasms (IPMNs) are common lesions

102 Intraductal papillary mucinous neoplasms (IPMNs) are the most freque

103 nes, the diagnostic criterion of intraductal papillary mucinous neoplasms (IPMNs) involving the main

104 dvances in radiographic imaging, Intraductal Papillary Mucinous Neoplasms (IPMNs) of the pancreas are

105 encountered in association with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.

106 sulted in increased detection of intraductal papillary mucinous neoplasms (IPMNs), and their manageme

107 nically, mucinous cysts, such as intraductal papillary mucinous neoplasms and mucinous cystic neoplas

108 ras(G12D) leads to predominantly intraductal papillary mucinous neoplasms and mucinous cystic neoplas

109 uld contribute to progression of intraductal papillary mucinous neoplasms into malignancies.

110 igh-risk lesions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 pancreatic intra

111 ed tumors (4/58, 6.9%) than non- intraductal papillary mucinous neoplasms PDAC (5/385, 1.3%) (P = .02

112 predicting malignant pancreatic intraductal papillary mucinous neoplasms were developed based on log

113 isk precursor neoplasms, such as intraductal papillary mucinous neoplasms with high-grade dysplasia a

114 de dysplasia, or intestinal-type intraductal papillary mucinous neoplasms with intermediate-grade dys

115 alignant potential (for example, intraductal papillary mucinous neoplasms).

116 st fluid samples of 169 PCLs (90 intraductal papillary mucinous neoplasms, 43 mucinous cystic neoplas

117 e and cyst fluid from pancreatic intraductal papillary mucinous neoplasms, the monoclonal antibody Da

118 d dMMR in a larger proportion of intraductal papillary mucinous neoplasms-related tumors (4/58, 6.9%)

119 the management of patients with Intraductal Papillary Mucinous Neoplasms.

120 lary" variant of adenocarcinoma, intraductal papillary mucinous tumors are observed in patients with

121 n the serum of healthy subjects, intraductal papillary mucosal neoplasms and pancreatic ductal adenoc

122 (32 [63%] male; mean age 61+/-15 years) with papillary muscle (n=18), fascicular (n=15), and mitral a

123 n=37; 38.1%), LV trabeculations (n=5; 5.2%), papillary muscle (n=3; 3.1%), and apical-septal bundle (

124 we sought to identify mitral valve (MV) and papillary muscle (PM) abnormalities that predisposed to

125 o by echocardiogram and in vitro by isolated papillary muscle analysis.

126 zing restrictive mitral annuloplasty (RA) or papillary muscle approximation with undersizing restrict

127 sually caused by chordae tendinae rupture or papillary muscle dysfunction.

128 KI hearts exhibited atrial enlargement, papillary muscle hypertrophy, and fibrosis.

129 oci being mapped at either the anterolateral papillary muscle or posteromedial papillary muscles of t

130 Papillary muscle retraction was combined with apical MI

131 Herein, we used skinned, ventricular papillary muscle strips from rats to investigate the eff

132 s study sought to investigate the benefit of papillary muscle surgery on long-term clinical outcomes

133 Under cardiopulmonary bypass, the papillary muscle tips in 6 sheep were retracted apically

134 Papillary muscle VAs were distinguished electrocardiogra

135 Patients with papillary muscle VAs were older and had higher prevalenc

136 thm, the accuracy rates for the diagnosis of papillary muscle VAs, fascicular VAs, and mitral annular

137 syndrome is characterized by fascicular and papillary muscle VE that triggers ventricular fibrillati

138 er in 6 of 6 cardiac arrest patients (4 from papillary muscle) and Purkinje origin of dominant VE was

139 in of dominant VE was seen in 5 of 8 (3 from papillary muscle) nonarrest patients.

140 ead morphology, can help distinguish between papillary muscle, fascicular, and mitral annular VAs.

141 ng from the left ventricular summit (n=4) or papillary muscles (n=2), 6 patients with noninfarct rela

142 Papillary muscles (PM) ventricular arrhythmias (VAs) exh

143 trophic cardiomyopathy phenotype observed in papillary muscles (PMs) of R58Q mice is also manifested

144 s, with a wide array of malformations of the papillary muscles and chordae, that can be detected by t

145 Fibrosis of the papillary muscles and inferobasal left ventricular wall,

146 nstability, left ventricular fibrosis in the papillary muscles and inferobasal wall, mitral annulus d

147 aflets and left ventricular (LV) fibrosis of papillary muscles and inferobasal wall.

148 Papillary muscles from male Sprague-Dawley rats were mou

149 mias (VAs) arising from the left ventricle's papillary muscles has been associated with inconsistent

150 is was detected at histology at the level of papillary muscles in all patients, and inferobasal wall

151 arction (MI), leaflet tethering by displaced papillary muscles induces mitral regurgitation (MR), whi

152 ications of catheter ablation of VA from the papillary muscles of the left ventricle with either cryo

153 erolateral papillary muscle or posteromedial papillary muscles of the left ventricle.

154 s force and [Ca(2+)]i measurements on intact papillary muscles show that enhancement of relaxation in

155 orce and [Ca(2+)]in measurements in isolated papillary muscles showed that the increased force and tw

156 cTnC for the thin filament in reconstituted papillary muscles to provide evidence of an allosteric m

157 The contractility of cardiac papillary muscles was also restored in CRISPR-edited car

158 RV trabeculations and papillary muscles were considered cavity volume.

159 ac MRI: LV trabeculations, LV myocardium, LV papillary muscles, and the LV blood cavity.

160 chanical stretch of the inferobasal wall and papillary muscles, eventually leading to myocardial hype

161 uctural heart disease can originate from the papillary muscles, fascicles, and mitral annulus.

162 ithin the body and to study the integrity of papillary muscles, the fibrous tissue of cardiac valve a

163 R attributable to unequal contraction of the papillary muscles, the magnitude of regurgitation is gre

164 ng histologic subtypes: chromophobe (n = 5), papillary (n = 5), and medullary (n = 2) RCC and unclass

165 ually rare BTC precursor lesion, intraductal papillary neoplasia (18.3%).

166 Intraductal papillary neoplasm of the biliary tract (B-IPN) is a sca

167 Intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas and bile duc

168 l mice developed severe dysplasia and cystic papillary neoplasms, there existed no apparent phenotypi

169 cal chemotherapy is recommended for low-risk papillary NMIBC, and induction intravesical chemotherapy

170 All patients had at least 1 left ventricular papillary or fascicular VE focus.

171 a from 324 histologically confirmed cases of papillary or follicular carcinoma, diagnosed from 1993 t

172 ining polyphenols with total differentiated, papillary, or follicular TC.

173 redominant histologic pattern-lepidic (LEP), papillary (PAP), acinar (ACN), micropapillary (MIP), or

174 ulate the genomic alterations found in human papillary (pRCC) and clear cell RCC (ccRCC), the most co

175 nal cell carcinomas (nccRCCs), consisting of papillary (pRCC), chromophobe (chRCC) and translocation

176 known as kidney renal clear cell carcinoma), papillary (pRCC, also known as kidney papillary) and chr

177 s include thick, irregular walls and septae; papillary projections and solid, echogenic foci.

178 reviously suspected simple cyst demonstrates papillary projections or solid areas at follow-up, then

179 pt segment that expressed TFF2 and overlying papillary projections.

180 subtypes, including clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC).

181 oth kidneys showed multifocal TSC-associated papillary RCC (PRCC).

182 c and screening biomarkers for clear cell or papillary RCC and in the differential diagnosis of image

183 be a prognostic biomarker for patients with papillary RCC and syntaxin 6 inhibitors hold promise as

184 ctively managed by using MRI to help predict papillary RCC for surveillance.

185 the data based on histological subtype, the papillary RCC subtype exhibited a significant correlatio

186 4, 100) for detecting malignancy, most often papillary RCC.

187 lower glucose uptake than clear cell RCC and papillary RCC.

188 eillance when MRI findings are indicative of papillary RCC.

189 xhibited the highest miR-126 expression, and papillary RCCs exhibited the lowest expression.

190 Eighteen of 20 papillary RCCs were hypovascular.

191 ation of clear cell RCC from chromophobe and papillary RCCs.

192 o severe upper and lower tarsal conjunctival papillary reaction, without corneal or eyelid changes an

193 enal intraepithelial neoplasia, and invasive papillary renal carcinoma.

194 a genomically quiet kidney tumor, clear cell papillary renal cell carcinoma (CCPAP).

195 e we investigate ITH and clonal evolution of papillary renal cell carcinoma (pRCC) and rarer kidney c

196 Purpose Patients with advanced papillary renal cell carcinoma (PRCC) have limited thera

197 Papillary renal cell carcinoma (pRCC) is an important su

198 Papillary renal cell carcinoma (PRCC) is the most common

199 omarkers to diagnose malignant clear cell or papillary renal cell carcinoma (RCC) in a screening para

200 development of an aggressive form of type 2 papillary renal cell carcinoma.

201 The histomorphological subtyping of papillary renal cell carcinomas (pRCCs) has improved the

202 Furthermore, type 2 papillary renal-cell carcinoma consisted of at least thr

203 is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms o

204 Papillary renal-cell carcinoma, which accounts for 15 to

205 as observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized b

206 Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinica

207 Type 1 and type 2 papillary renal-cell carcinomas were shown to be differe

208 ve molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome seque

209 In situ, the papillary reticular boundary was indistinguishable in th

210 ed in high-grade primary tumor patients with papillary serous tumors of the ovary.

211 ORR was higher in patients with significant papillary (seven of 18) or chromophobe (two of five) ele

212 linear correlation between EOD duration and papillary size.

213 hese results extend previous observations of papillary stem cell activity and collecting duct plastic

214 -) and KC/Tff2(-/-) mice developed prominent papillary structures in the duct epithelium with cystic

215 iagnosis of indolent and well-differentiated papillary subtype and early-stage thyroid cancer, wherea

216 olic pathway utilization distinguish EMT and papillary subtypes of breast cancer and identify said pa

217 ces in nucleotide metabolism between EMT and papillary subtypes.

218 that can distinguish between clear cell and papillary subtypes.

219 thelial-mesenchymal transition (EMT) and the papillary subtypes.

220 acid was also inversely associated only with papillary TC (ORlog2: 0.68; 95% CI: 0.51, 0.91).

221 m healthy donors were primed in vitro with a papillary TC or ATC cell line conditioned medium (CM) or

222 ATC CM induce NET release, whereas papillary TC or normal thyroid CM did not.

223 and ferulic acids may be related to a lower papillary TC risk.

224 Similar results were observed for papillary TC, but not for follicular TC.

225 010-2013), primarily related to increases in papillary thyroid cancer (annual percent change, 4.4% [9

226 ts, and subgroup analyses were performed for papillary thyroid cancer (n = 341) and follicular thyroi

227 mutated gene in malignant melanoma (MM) and papillary thyroid cancer (PTC) and is causally involved

228 d to clarify whether aggressive histology of papillary thyroid cancer (PTC) impacts overall survival

229 Papillary thyroid cancer (PTC) is the most common type o

230 shown to be highly associated with increased papillary thyroid cancer (PTC) risk with an odds ratio o

231 leotide polymorphisms (SNPs) associated with papillary thyroid cancer (PTC) risk.

232 Papillary thyroid cancer (PTC) was diagnosed in 97% of p

233 lysed a multi-generation CS-like family with papillary thyroid cancer (PTC), applying a combined link

234 ty risk factor in the risk stratification of papillary thyroid cancer (PTC), but whether this is gene

235 nsidered to play a unique prognostic role in papillary thyroid cancer (PTC), with a distinct staging

236 on of a murine model of Braf(V600E) -induced papillary thyroid cancer (PTC).

237 ells (MSCs) in non-carcinogenic thyroids and papillary thyroid cancer (PTC).

238 E and TERT promoter mutations can coexist in papillary thyroid cancer (PTC).

239 E and TERT promoter mutations can coexist in papillary thyroid cancer (PTC).

240 patients with clinically node negative (cN0) papillary thyroid cancer (PTC).

241 only in patients age 45 years or older with papillary thyroid cancer (PTC); patients younger than ag

242 l disease risk in patients after surgery for papillary thyroid cancer as a function of primary tumor

243 tor antagonism, chemical concentrations, and papillary thyroid cancer case status.

244 unclear whether the increasing incidence of papillary thyroid cancer has been related to thyroid can

245 About half of patients with papillary thyroid cancer have tumours with activating BR

246 in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial.

247 Papillary thyroid cancer incidence increased for all SEE

248 a from the largest subgroup, that is, female papillary thyroid cancer patients.

249 ients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodin

250 ologically confirmed recurrent or metastatic papillary thyroid cancer refractory to radioactive iodin

251 ent, and a long noncoding RNA (lncRNA) gene, papillary thyroid cancer susceptibility candidate 2 (PTC

252 sence of MSCs with a fibrotic fingerprint in papillary thyroid cancer tumors and the autocrine-paracr

253 iagnosed with thyroid cancer from 1974-2013, papillary thyroid cancer was the most common histologic

254 t patients diagnosed with localized >/= 1-cm papillary thyroid cancer who underwent thyroidectomy wit

255 Patients who undergo surgery for papillary thyroid cancer with only a limited lymph node

256 eptor kinase that undergoes rearrangement in papillary thyroid cancer).

257 urgeons and pathologists in the treatment of papillary thyroid cancer, and especially intermediate-ri

258 g the kinase domain are oncogenic drivers in papillary thyroid cancer, non-small-cell lung cancer, an

259 overshadowed by its more common counterpart-papillary thyroid cancer-despite its unique biological b

260 Papillary thyroid cancer-specific mortality for cases wi

261 Papillary thyroid cancer-specific mortality occurred in

262 Results: Papillary thyroid cancer-specific mortality occurred in

263 st 4 decades, driven largely by increases in papillary thyroid cancer.

264 ve of disease-free survival in patients with papillary thyroid cancer.

265 r (95% CI, 1.1%-4.7%) for SEER distant stage papillary thyroid cancer.

266 oid cancer mortality rate for advanced-stage papillary thyroid cancer.

267 ina participating in a case-control study on papillary thyroid cancer.

268 afenib in patients with BRAF(V600E)-positive papillary thyroid cancer.

269 ten (Braf(V600E)/Pten(-/-)/TPO-Cre) leads to papillary thyroid cancers (PTC) that rapidly progress to

270 E) mutation is found in approximately 40% of papillary thyroid cancers (PTC).

271 he Cancer Genome Atlas study (TCGA study) of papillary thyroid cancers (PTC).

272 positive tumors, including MNG, schwannomas, papillary thyroid cancers (PTCs), and Wilms tumors.

273 ncluding undifferentiated sarcomas, gliomas, papillary thyroid cancers, spitzoid neoplasms, inflammat

274 A substantial increase in papillary thyroid carcinoma (PTC) among children exposed

275 ological examination of the mass confirmed a papillary thyroid carcinoma (PTC) and enlarged metastati

276 Papillary thyroid carcinoma (PTC) displays strong but so

277 Papillary thyroid carcinoma (PTC) is the most common his

278 Papillary thyroid carcinoma (PTC) remained to be the mos

279 Papillary thyroid carcinoma (PTC), the most frequent thy

280 NP (rs965513) firmly associated with risk of papillary thyroid carcinoma (PTC).

281 thyroidectomy caused by local recurrence of papillary thyroid carcinoma is extremely rare.

282 Papillary thyroid carcinoma overexpress transforming gro

283 We report a case of papillary thyroid carcinoma which invades IJV with hyper

284 osomal rearrangements found in radio-induced papillary thyroid carcinoma.

285 thrombosis is an extremely rare condition in papillary thyroid carcinoma.

286 sequencing and expression analysis of eight papillary thyroid carcinomas (PTC) to comprehensively ch

287 he number of genetic alterations detected in papillary thyroid carcinomas (PTC).

288 Papillary thyroid carcinomas (PTCs) account for 90% of h

289 In papillary thyroid carcinomas, COMET was part of a coexpr

290 ons drive differential pathway activation in papillary thyroid carcinomas, leading to different tumor

291 especially in BRAF-mutated and MET-addicted papillary thyroid carcinomas.

292 They are likely to develop from papillary thyroid microcarcinomas (PTMCs), found in up t

293 Management of papillary thyroid microcarcinomas should take into accou

294 able to the identification of intrathyroidal papillary thyroid microcarcinomas.

295 and water transport from Bowman space to the papillary tip of the nephron of a human kidney.

296 s of five distinct treatment naive tumors, a papillary transitional cell renal cell carcinoma, a duod

297 used the nucleotide salvage pathway, whereas papillary tumors preferred de novo nucleotide biosynthes

298 cinoma in situ) or recurrence-free rate (for papillary tumors) of at least 50% at 6 months, 30% at 12

299 or 3 (FGFR3) occur in up to 80% of low-grade papillary urothelial carcinoma of the bladder (LGP-UCB)

300 0T converted carcinoma-in-situ to high-grade papillary urothelial carcinoma.